Company Overview of Merck Research Laboratories
Merck Research Laboratories discovers and develops medicines for cancer and neurodegenerative disorders. The company was founded in 2004 and is based in Boston, Massachusetts. Merck Research Laboratories operates as a subsidiary of Merck & Co. Inc.
33 Avenue Louis Pasteur
Boston, MA 02115
Founded in 2004
Key Executives for Merck Research Laboratories
Senior Vice President of Human Genetics and Vaccines Discovery
Senior Vice President and Franchise Head of Immunology Respiratory & Endocrine
Senior Vice President and Franchise Head of Diabetes & Obesity
Senior Vice President and Head of Franchise
Compensation as of Fiscal Year 2014.
Merck Research Laboratories Key Developments
Merck Research Laboratories Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 through Sep-24-2014
Sep 10 14
Merck Research Laboratories Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 through Sep-24-2014. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Presentation Date & Speakers: Sep-22-2014, John Delyani, Executive Director, Business Development and Licensing. Sep-24-2014, Benjamin Thorner, Associate VP, Head of Business Development and Licensing, Boston Innovation Hub.
Merck Research Laboratories Announces Encouraging Data from Phase Ib Melanoma Study
Jun 4 14
Merck Research Laboratories has announced encouraging data from its ongoing Phase Ib study, KEYNOTE-001, evaluating pembrolizumab, its investigational anti-PD-1 antibody, as a single agent in 411 patients with advanced melanoma. Following treatment with pembrolizumab, the estimated overall survival (OS) rate at one year was 69% across all patients studied, including 74% in patients without prior ipilimumab therapy (current standard therapy) and 65% in patients who had progressive disease on or following ipilimumab. At 18 months, the estimated OS was 62%. The median OS has not been reached, with some patients receiving treatment with pembrolizumab as monotherapy for more than two years. These data from 411 patients with advanced melanoma enrolled in multiple cohorts from KEYNOTE-001 will be highlighted as part of the ASCO 2014 Press Program. KEYNOTE-001 involved seven advanced melanoma cohorts including patients with varying stages of disease and prior lines of therapy. At baseline, 56% of patients had the most advanced stage of disease (M1c) (n=232) and 77% of patients had received at least one prior systemic therapy (n=316). At the time of analysis, 88% of reported responses in evaluable patients were ongoing and the median duration of response, by RECIST criteria, had not been reached (n=115/130) (range 6+ weeks to 76+ weeks). The median progression-free survival (PFS), by RECIST criteria, was 5.5 months overall (95% CI, 3.8-6.2), including 5.6 months in patients with no prior ipilimumab therapy (95% CI, 3.7-11) and 5.4 months in patients who had progressive disease on or following ipilimumab therapy (95% CI, 3.2-5.6). Anti-tumor activity was observed across all doses studied, regardless of the type and number of previous treatments (including prior ipilimumab therapy), performance status, Lactate Dehydrogenase (LDH) levels, BRAF mutation status, tumor size at baseline, and anatomical site of metastatic disease. An analysis of patient subgroups indicates that lower tumor burden at baseline is a strong predictor of response to pembrolizumab.
Merck Research Laboratories Presents at BioNJ 2014 International BioPartnering Conference, Apr-10-2014 08:30 AM
Apr 2 14
Merck Research Laboratories Presents at BioNJ 2014 International BioPartnering Conference, Apr-10-2014 08:30 AM. Venue: The Westin Princeton, Forrestal Village, New Jersey, United States. Speakers: Iain D. Dukes, SVP, Business Development and Licensing.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|